

**GI Oncology Multidisciplinary Case Conference and Tumor Board 2025-2026 - 7/9/2025**

**July 9, 2025**

**1:30 PM - 2:30 PM**

**PCAM South Tower 12th Floor Conference Room 12-122 and/or via MS Teams**

**Target Audience**

This program has been designed for DIAGNOSTIC RADIOLOGY, CLINICAL GENETICS AND GENOMICS (MD), INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - CLINICAL, INTERNAL MEDICINE - Gastroenterology, INTERNAL MEDICINE, DIAGNOSTIC MEDICAL PHYSICS, COLON AND RECTAL SURGERY, PATHOLOGY - ANATOMIC, MEDICAL GENETICS AND GENOMICS - Medical Biochemical Genetics, MEDICAL GENETICS AND GENOMICS - Molecular Genetic Pathology

**Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss and collaborate on the patient's treatment plan in an interprofessional and interdisciplinary setting.
- 2 Describe state-of-the-art diagnostic and treatment methods for the conditions presented, incorporating the latest evidence-based practices.
- 3 Describe and apply the standard of care for patient management, as outlined in national practice guidelines.

**Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

For more information, please contact  
**Roberto Lorenzo, Franklin Ingram**  
**(215) 349-5955, (267) 240-0583**

**roberto.lorenzo@uphs.upenn.edu, frank.ingram@pennmedicine.upenn.edu**

**Check your transcript online at <https://upenn.cloud-cme.com>**



### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
John Plastaras, MD	Other Planning Committee Member	Nothing to disclose - 06/06/2025
Nevena Damjanov, MD	Other Planning Committee Member	Nothing to disclose - 10/10/2024
Elizabeth PrechtelDunphy, CRNP RN	Other Planning Committee Member	Honoraria-Incyte Corporation   Other: Chair or Virtual Advisory Board-Astra Zeneca Pharmaceuticals - 08/08/2024
Ursina Teitelbaum, MD	Co-Director, Faculty	Nothing to disclose - 11/04/2024
Et-Tsu Chen, MD	Other Planning Committee Member	Nothing to disclose - 04/22/2025
Hanna Zafar, MD	Other Planning Committee Member	Nothing to disclose - 03/20/2025
Mark Rosen, MD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
Evan S Siegelman, MD	Other Planning Committee Member	Paid consultant-Icon Medical Imaging   Paid consultant-Bioclinica Inc   Paid consultant-Invicro Inc (Relationship has ended)   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Covera - 06/03/2025
Tracy d'Entremont, MD	Other Planning Committee Member	Nothing to disclose - 11/17/2024
Pallavi Kumar, MD	Other Planning Committee Member	Nothing to disclose - 10/09/2024
Parul Agarwal, MD	Other Planning Committee	Nothing to disclose - 05/07/2025

	Member	
Kim Reiss Binder, MD	Other Planning Committee Member	Advisor-Carisma Therapeutics (Relationship has ended)  Advisor-Bristol-Myers Squibb  Advisor-Foundation Medicine  Advisor-Astra Zeneca Pharmaceuticals  Grant or research support-Clovis Oncology (Relationship has ended)  Grant or research support-Bristol-Myers Squibb  Grant or research support-Glaxo Smith Kline - 03/07/2025
Maureen Hewitt, MD	Other Planning Committee Member	Nothing to disclose - 09/10/2024
Rashmi Tondon, MD	Other Planning Committee Member	Nothing to disclose - 01/22/2025
Charles J Schneider, MD	Other Planning Committee Member	Nothing to disclose - 10/11/2024
Ronald P DeMatteo, MD	Other Planning Committee Member	Nothing to disclose - 10/21/2024
Edgar Ben-Josef, MD	Course Director	Nothing to disclose - 06/03/2025
Emma Furth, MD	Other Planning Committee Member	Nothing to disclose - 09/06/2024
Mark O'Hara, MD	Other Planning Committee Member	Grant or research support-Bristol-Myers Squibb  Grant or research support-Genmab  Grant or research support-Hibercell (Relationship has ended)  Grant or research support-Arcus Biosciences  Grant or research support-Bellicum (Relationship has ended)  Grant or research support-Natera (Relationship has ended)  Grant or research support-Celldex (Relationship has ended)  Grant or research support-Psioxus  Consulting Fee-Geneos (Relationship has ended)  Advisor-Alligator Bioscience  Grant or research support-Geistlich  Grant or research support-Triumvera (Relationship has ended)  Consulting Fee-Merus (Relationship has ended)  Grant or research support-Elicio  Grant or research support-Revolution Medicine  Grant or research support-Verastem  Grant or research support-Astra Zeneca Pharmaceuticals - 10/17/2024
James Metz, MD	Other Planning Committee Member	Nothing to disclose - 09/17/2024
Erin Davis, CRNP RN	Nurse Planner	Nothing to disclose - 01/13/2025
Danielle Fortuna, MD	Other Planning Committee Member	Nothing to disclose - 01/06/2025
Kathryn Green, CRNP	Other Planning Committee Member	Speakers Bureau-Aadi bio  Speakers Bureau-Astra Zeneca Pharmaceuticals - 09/11/2024
Amr K El Jack, MD, PhD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
Patricia Gambino, MSN	Other Planning Committee Member	Nothing to disclose - 09/13/2024

Charles M Vollmer Jr., MD	Other Planning Committee Member	Nothing to disclose - 09/05/2024
Major K Lee IV, MD, PhD	Other Planning Committee Member	Nothing to disclose - 09/24/2024
Zhaohai Yang, MD, PhD	Other Planning Committee Member	Consulting Fee-Flagship Biosciences - 01/02/2025
Adam F\ Fredo, PA-C	Physician Assistant Planner	Nothing to disclose - 01/17/2025
William Chapin, MSCE	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Replimune   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merus  Grant or research support-Merus  Grant or research support-Genentech  Grant or research support-Replimune   Grant or research support-Boehringer-Ingelheim  Other: Travel Support - Dava Oncology (Relationship has ended) - 05/22/2025
Robin Collingwood, MD	Other Planning Committee Member	Nothing to disclose - 08/15/2024
Ryan Massa, MD	Other Planning Committee Member	Nothing to disclose - 01/17/2025
Joanie Garratt, MD	Other Planning Committee Member	Nothing to disclose - 11/21/2024
Debra Whorms, MD	Other Planning Committee Member	Nothing to disclose - 04/10/2025
Hersh Sagreiya, MD, FCBC	Other Planning Committee Member	Nothing to disclose - 02/10/2025
Lisa P Jones, MD, PhD	Other Planning Committee Member	Nothing to disclose - 11/30/2024
Hyun Tae Kim, MD, MPH	Other Planning Committee Member	Nothing to disclose - 11/14/2024
Galen Leung, MD	Other Planning Committee Member	Paid consultant-Steris   Advisor-Boston Scientific Corporation   Advisor-AI Medical Service   Consulting Fee-Mirai Medical - 09/14/2024
Sherry Shang, MD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
Kalpana Suresh, MD	Other Planning Committee Member	Nothing to disclose - 09/07/2024
Kristen Stashek, MD	Other Planning Committee Member	Nothing to disclose - 04/14/2025
Matthew Nazarian, MD	Other Planning Committee Member	Nothing to disclose - 05/07/2025
Ali Dhanaliwala, MD, PhD	Other Planning Committee Member	Nothing to disclose - 01/06/2025
Karishma Khullar, MD	Other Planning Committee Member	Nothing to disclose - 10/09/2024
Emma Briscoe, MSN	Other Planning Committee Member	Nothing to disclose - 09/19/2024
Efrat Dotan, MD	Other Planning Committee Member	Advisor-Ipsen (Relationship has ended)  Advisor-Merus (Relationship has

		ended)  Consulting Fee-Olympus (Relationship has ended)  Advisor-Amgen (Relationship has ended)  Advisor-Agenus (Relationship has ended)  Advisor-Merck & Co (Relationship has ended)  Grant or research support-Ipsen - 01/30/2025
Shuchi K Rodgers, MD	Other Planning Committee Member	Royalties or Patent Beneficiary-Elsevier - 01/21/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected